LabCentral exists at the epicenter of the biotech world: between revered colleges and universities, esteemed research institutions, and pharmaceutical giants. We are honored and excited to be a part of a growing industry pushing the boundaries of science to address the toughest challenges in human health.

We are incredibly grateful for the support we continue to receive from our sponsors, partners, network, and friends, and look forward to continuing to provide start-ups the best place to grow in the coming years.

126 companies supported by LabCentral since opening in 2013

$5.9B raised (all sources) by LabCentral Resident and Alumni companies since 2013

2395 jobs added in Massachusetts by LabCentral Resident and Alumni Companies since 2013

20% of the National Series A funding secured by LabCentral companies in 2019

*Of 126 companies tracked in 2019, 63% self-reported. Others were tracked using data available on Pitchbook.
**As compared to SVB’s Healthcare Investments & Exits Report 2020
AN ECONOMIC ENGINE
Driving Innovation

$582 Million closed in Series A
Funding closed by Resident and Alumni companies in 2019

124 sponsor relationships
existed with our Resident and Alumni in 2019

13% of LabCentral Alumni
Have had successful M&As or IPOs

789 scientists and entrepreneurs
within our Resident and Alumni networks

Our OVID-19 Response

Many LabCentral Resident and Alumni companies have pivoted their technologies to address the pandemic including Aldatu Biosciences, Sentien Biotechnologies, Affinivax, and Vaxess Technologies, and we are proud to highlight how we have worked to support the work of teams addressing the crisis head-on.

By 2018, LabCentral became the 4th largest “state” in the U.S. for early stage investment.

Investment in LabCentral companies is growing at ~66% per year

Total Funding Breakdown by Source

- VC
- Grants/Angel
- Corporate/Partnerships
- Other Funding/Revenue
- Exits (IPO/M&A)

Breakdown by Source

Total Funding: $2,500
$2,000
$1,500
$1,000
$500
$0

2017
2018
2019

Total Funding by Source

VC
Grants/Angel
Corporate/Partnerships
Other Funding/Revenue
Exits (IPO/M&A)

Years: 2017, 2018, 2019

Investment in LabCentral companies is growing at ~66% per year

By 2018, LabCentral became the 4th largest “state” in the U.S. for early stage investment.
Minimizing Friction

We ease the way for companies to get started with their science quickly in the lab, decrease the capital and resources needed for basic operations and provide hundreds of services that allow them to focus on what they do best: further their science and build their business.

- 188 gallons of 70% ethanol used, the equivalent of 28,074.67 cocktails
- 67 pieces of new equipment added to our laboratories in 2019
- 156 terrabytes of data down/up loaded; the equivalent of >15 years of Hubble Telescope images

Increasing Collisions

We accomplish our role in building relationships (both intentional and unintentional) in many ways. Much of this takes place in our events and programs for residents, alumni, sponsors, and the greater community. With the help of our 44 sponsors, we are able to provide Residents and Alumni hundreds of introductions to potential partners and accelerate their scientific progress and growth.

- 239 events & >250 lab trainings
- 111,104 orders placed through our purchasing platform for resident companies, totaling $23,593,058 in supplies and equipment

---

Community Connection
Events
Business Development
Trainings
Technical & Scientific Programs
STEM Education & Outreach
The LabCentral Network

As our companies have grown over the last five years, we have grown with them, creating a pipeline of spaces and tools purpose built to start-up companies’ needs at every stage of their development. These new facilities have been in direct response to needs we hear from our resident companies, the entrepreneurial community, and our industry partners. These spaces are fueling the economic engine that is the life-sciences economy.

Working With Our Community

At LabCentral, we are proud to say we are supporting not only the next generation of biotech startups, but also the next-generation of scientists, entrepreneurs, and thinkers. In 2019, we began a new initiative dedicated to enabling opportunity through partnerships with workforce and career pipeline organizations with a lens towards diversity and inclusion of both the under-represented in our industry and the under-served in our community.

LabCentral 238 is designed to facilitate the transition of start-ups in their process development and engineering, preparing them for GMP of their game-changing technologies. LabCentral 238 will provide approximately 100,000 square feet of labs, offices, shared process development, and scale-up resources.

LabCentral’s Summer Intern Cohort of 2019 featured a group of students with diverse backgrounds and areas of study ranging from seniors in high school, to students in their final undergraduate year. Students were given cross-functional opportunities within our team and have completed meaningful work in support of our basic operations and mission-driven activities. Additionally, 22% of Resident company interns at LabCentral in 2019 came from non-profit educational programs empowering young people from under-represented demographics to explore in science and technology.

42 LabCentral team members supporting operations across 120,000 square feet of space.